Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radiation Risks Of Interventional Fluoroscopy Examined At FDA Meeting

This article was originally published in The Gray Sheet

Executive Summary

The use of fluoroscopic imaging during interventional procedures such as cardiovascular catheterizations raises unique radiation exposure issues that must be examined apart from those for diagnostic imaging

You may also be interested in...



FDA Aims To Educate Makers Of Fluoroscopic X-Ray Systems In Its Latest Final Guidance

A new guidance document from the US FDA clarifies the agency's current thinking on targeted portions of its performance standard requirements for the X-ray systems.

FDA Says It Will Accept International Standard On Fluoroscopic Equipment

FDA plans to accept a declaration of conformity to an international standard for fluoroscopic equipment even though it does not perfectly the match the performance standard found in FDA regulations, the agency said in draft guidance.

Industry Unveils Radiation Therapy Patient Protection Effort At FDA Meeting

Manufacturers of linear accelerators and other devices for radiation oncology treatments are endorsing an industry "Radiation Therapy Readiness Check Initiative" to help prevent treatment errors

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel